The hepatitis B virus (HBV) is a major cause of cirrhosis and hepatocellular carcinoma
worldwide. Despite an effective vaccine, the prevalence of chronic infection remains high …

Prevention of mother-to-child transmission of hepatitis B virus (HBV) infection is a
cornerstone of efforts to support progress towards elimination of viral hepatitis. Current …

To facilitate the achieving of the goal of" eliminating viral hepatitis as a major public health
threat by 2030" set by the World Health Organization, the Chinese Society of Hepatology …

Background The nucleos (t) ide analogues (NAs) entecavir (ETV), tenofovir disoproxil
fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients …

Background & Aims Data on long-term tenofovir alafenamide (TAF) therapy for pregnant
women with active chronic hepatitis B (CHB)(immune clearance and reactivation phases …

加强慢性HBV 感染孕妇及其所分娩婴儿的规范化管理是切断HBV 母婴传播,
确保母婴安全和降低儿童慢性HBV 感染的最主要措施. 孕妇和儿童是特殊人群, 慢性HBV …

Hepatitis B virus (HBV) is a global health problem. Vertical transmission of HBV from HBV
surface antigen (HBsAg)‐positive mothers to their infants is the most common cause of HBV …

Objective Tenofovir disoproxil fumarate (TDF) is recommended for the prevention of mother-
to-infant transmission of the hepatitis B virus (HBV). This study investigated the safety of …

Hepatitis B is a major public health threat, responsible for approximately 820,000 deaths in
2019 alone. 1 It is estimated that approximately 262 million people are living with hepatitis B …

Introduction Tenofovir alafenamide (TAF), a prodrug of tenofovir, achieves higher
intracellular concentrations of tenofovir-diphosphate and 90% lower plasma concentrations …